Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent <i>Clostridioides difficile</i> Infection in a Randomized Clinical Trial
Stuart H. Cohen, Thomas Louie, Matthew Sims, Elaine E. L. Wang, Aslı Memişoğlu, Barbara McGovern, Lisa Von Moltke
Abstract
This study examines adverse events and durability of response of SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, compared with placebo for Clostridioides difficile infection.
Topics & Concepts
ClostridioidesMedicineFirmicutesMicrobiomeAdverse effectPlaceboRandomized controlled trialClostridium difficileInternal medicineMicrobiologyAntibioticsBioinformaticsPathologyBacteriaAlternative medicine16S ribosomal RNAGeneticsBiologyClostridium difficile and Clostridium perfringens researchGut microbiota and healthNosocomial Infections in ICU